Why UDX
Disruptive European Start-up fighting the war to make
cancer a curable disease.
1. A test with a unique value proposition
- Early detection: CRC detection on early stages.
- CRC prevention: Adenoma detection prevents CRC before it appears.
- Higher accuracy: >85% sensitivity and specificity on CRC and advanced adenoma.
- Non-invasive: Just a blood sample.
- Inexpensive: Its cost-efficient technological platform makes the test accessible to all.
2. With huge benefits for society & medical practice
- Increase of CRC detection and survival rates: Through higher compliance and early detection.
- Increase of screening compliance: Blood sampling preferred to fecal sampling (FIT) and colonoscopy.
- Reduction of unnecessary colonoscopies performed: Healthy or non-advanced adenoma detected individuals would not require colonoscopy.
- Convenient test for clinicians, hospitals, screening programs and insurance companies: Accurate, non-invasive, easy to use and inexpensive.
3. Company with solid scientific know-how determined to transform cancer diagnostics
- Top-tier international team: Experienced scientists and tech entrepreneurs.
- Prestigious Scientific Advisory Board: Key opinion leaders in the areas of gastroenterology, oncology and diagnostics.
- World-class network of international alliances: Leading technological and medical institutions.
- Top group of private investors: Global high tech entrepreneurs and investors.
- Singularity University “Most disruptive start-up” award winner: At Exponential Medicine, 2015.
- Innovative technological platform: Method expandable to different types of cancer with high through-put.
- Addressing a key unmet need: A huge market opportunity.
- Company highly committed with Quality- See Quality Policy
